These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19053772)

  • 21. Activity of sulfonium bisphosphonates on tumor cell lines.
    Zhang Y; Hudock MP; Krysiak K; Cao R; Bergan K; Yin F; Leon A; Oldfield E
    J Med Chem; 2007 Nov; 50(24):6067-79. PubMed ID: 17963374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Vitro and In Vivo Activities of Sulfur-Containing Linear Bisphosphonates against Apicomplexan Parasites.
    Szajnman SH; Galaka T; Li ZH; Li C; Howell NM; Chao MN; Striepen B; Muralidharan V; Moreno SN; Rodriguez JB
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of new potent inhibitors of farnesyl pyrophosphate synthase.
    Prokopenko V; Kovalishyn V; Shevchuk M; Kopernyk I; Metelytsia L; Romanenko V; Mogilevich S; Kukhar V
    Curr Drug Discov Technol; 2014 Jun; 11(2):133-44. PubMed ID: 24818603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonate metal complexes as selective inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase.
    Demoro B; Caruso F; Rossi M; Benítez D; González M; Cerecetto H; Galizzi M; Malayil L; Docampo R; Faccio R; Mombrú AW; Gambino D; Otero L
    Dalton Trans; 2012 Jun; 41(21):6468-76. PubMed ID: 22344249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase.
    Szajnman SH; García Liñares GE; Li ZH; Jiang C; Galizzi M; Bontempi EJ; Ferella M; Moreno SN; Docampo R; Rodriguez JB
    Bioorg Med Chem; 2008 Mar; 16(6):3283-90. PubMed ID: 18096393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes.
    Mao J; Mukherjee S; Zhang Y; Cao R; Sanders JM; Song Y; Zhang Y; Meints GA; Gao YG; Mukkamala D; Hudock MP; Oldfield E
    J Am Chem Soc; 2006 Nov; 128(45):14485-97. PubMed ID: 17090032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
    Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacophoric studies of in vitro inhibition of Plasmodium falciparum growth.
    Hariharan S
    Indian J Biochem Biophys; 2012 Apr; 49(2):101-8. PubMed ID: 22650007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
    Dunford JE
    Curr Pharm Des; 2010; 16(27):2961-9. PubMed ID: 20722615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The intracellular target for the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase.
    Grove JE; Brown RJ; Watts DJ
    J Bone Miner Res; 2000 May; 15(5):971-81. PubMed ID: 10804029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors.
    Liu J; Liu W; Ge H; Gao J; He Q; Su L; Xu J; Gu LQ; Huang ZS; Li D
    Biochim Biophys Acta; 2014 Mar; 1840(3):1051-62. PubMed ID: 24246954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
    Savino S; Toscano A; Purgatorio R; Profilo E; Laghezza A; Tortorella P; Angelelli M; Cellamare S; Scala R; Tricarico D; Marobbio CMT; Perna F; Vitale P; Agamennone M; Dimiccoli V; Tolomeo A; Scilimati A
    Eur J Med Chem; 2018 Oct; 158():184-200. PubMed ID: 30216851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineered gene over-expression as a method of drug target identification.
    Sugden CJ; Roper JR; Williams JG
    Biochem Biophys Res Commun; 2005 Aug; 334(2):555-60. PubMed ID: 16005849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
    Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
    J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Farnesyl diphosphate synthase inhibitors from in silico screening.
    Lindert S; Zhu W; Liu YL; Pang R; Oldfield E; McCammon JA
    Chem Biol Drug Des; 2013 Jun; 81(6):742-8. PubMed ID: 23421555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorescent Farnesyl Diphosphate Analogue: A Probe To Validate trans-Prenyltransferase Inhibitors.
    Teng KH; Hsu ET; Chang YH; Lin SW; Liang PH
    Biochemistry; 2016 Aug; 55(31):4366-74. PubMed ID: 27428767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based virtual screening and biological evaluation of novel non-bisphosphonate farnesyl pyrophosphate synthase inhibitors.
    Liu Q; Miao Y; Wang X; Lv G; Peng Y; Li K; Li M; Qiu L; Lin J
    Eur J Med Chem; 2020 Jan; 186():111905. PubMed ID: 31785819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3D-QSAR, molecular docking, and ONIOM studies on the structure-activity relationships and action mechanism of nitrogen-containing bisphosphonates.
    Liu QZ; Wang SS; Li X; Zhao XY; Li K; Lv GC; Qiu L; Lin JG
    Chem Biol Drug Des; 2018 Mar; 91(3):735-746. PubMed ID: 29080272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular characterization of a novel geranylgeranyl pyrophosphate synthase from Plasmodium parasites.
    Artz JD; Wernimont AK; Dunford JE; Schapira M; Dong A; Zhao Y; Lew J; Russell RG; Ebetino FH; Oppermann U; Hui R
    J Biol Chem; 2011 Feb; 286(5):3315-22. PubMed ID: 21084289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
    Dunford JE; Kwaasi AA; Rogers MJ; Barnett BL; Ebetino FH; Russell RG; Oppermann U; Kavanagh KL
    J Med Chem; 2008 Apr; 51(7):2187-95. PubMed ID: 18327899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.